Iroko launches Zorvolex in Lebanon for acute and chronic pain

In December last year, the Republic of Lebanon Ministry of Public Health (MOPH) approved Zorvolex as a new chemical entity to treat mild to moderate acute pain in adults and osteoarthritis pain.

Iroko Board executive chairman and CEO Osagie Imasogie said: "We are pleased to announce that Zorvolex is now available in Lebanon for both acute and chronic pain conditions, providing a low dose treatment option to patients and prescribers in the country.

"This first international launch of Zorvolex demonstrates our commitment to working with global partners to commercialize Zorvolex, and marks an important step in bringing our low dose NSAIDs to patients around the world."

The approval was result of a licensing agreement signed in late 2013 by Iroko and Algorithm under which the latter had secured the exclusive rights to register and market Zorvolex in countries in the Middle East and North Africa (MENA).

In addition, Algorithm is planning to submit product registration applications for Zorvolex to other countries across the MENA region this year and next.

The US Food and Drug Administration (FDA) has approved Zorvolex to manage mild to moderate acute and osteoarthritis pain, and is available at pharmacies across the US.

Iroko Pharmaceuticals, an affiliate of Iroko Pharmaceuticals, will continue to retain all marketing rights to Zorvolex in the US.

Zorvolex, the first FDA-approved low dose NSAID developed using proprietary SoluMatrix Fine Particle Technology, and it is currently available by prescription.